R. Hector MacKay-Dunn
R. Hector MacKay-Dunn , QC
Partner at FARRIS
(604) 661-9307
(604) 661-9349
700 West Georgia St, FL 25, Vancouver, BC
Year called to bar: 1978 (BC); 2014 (ON); 2014 (AB)
Senior partner Hector MacKay-Dunn has 30+ years of experience providing advice to high-growth public and private companies and public institutions, over a broad range of industry sectors including life sciences, technology, health, mining and clean tech, advising on corporate domestic & cross-border public & private securities offerings, M&A, international partnering & licensing transactions, and to boards of directors and independent board committees on corporate governance matters. Hector is recognized by Lexpert® in the 2020 Lexpert® Special Editions on Energy, Global Mining, Infrastructure, and Technology; by Best Lawyers as Lawyer of the Year 2020 in Biotech, in Canada in Biotech, M&A, tech, and corporate & securities 2021; and in Chambers Canada 2021. Hector received the 2014 LifeSciences Milton Wong Leadership Award, Queen’s Counsel (BC) designation in 2003, and AV Preeminent rating from Martindale-Hubbell. Hector has served as board member with a number of private and public companies and the board of the BC Tech Association, board and executive committee member of Tennis Canada, chair of the BC Innovation Council, and Genome BC. Admitted to the BC, Alberta, and Ontario Bars.
R. Hector MacKay-Dunn is also listed in the following publication(s)
Read more about R. Hector MacKay-Dunn in ...
Tech deals jump in value
To every cloud there is a silver lining, and several sectors of the economy have been thriving during the pandemic — especially those related to the pandemic
On April 12, 2018, Arbutus Biopharma Corporation (Arbutus), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Roivant Sciences Ltd. (Roivant) announced that they have entered into an agreement to launch Genevant Sciences (Genevant), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute US$37.5 million in transaction-related seed capital for Genevant.
On January 12, 2018, Arbutus Biopharma Corp. (Arbutus) closed on a transaction involving the issue and sale of 664,000 series A participating convertible preferred shares of Arbutus (Preferred Shares) to Roivant Sciences Ltd. (Roivant) for gross proceeds to Arbutus of US$66.4 million (Tranche 2).
Tekmira Pharmaceuticals Corporation completed an offering of 7,500,000 common shares at a price of US$20.25 per share for gross proceeds of approximately US$151.9 million.
Intrexon Corporation (Intrexon) completed its acquisition of Okanagan Specialty Fruits Inc. (OSF) by way of statutory plan of arrangement pursuant to which a wholly-owned subsidiary of Intrexon acquired all the securities of OSF for US$41 million. OSF shareholders received US$31 million in Intrexon common stock and US$10 million in upfront cash, subject to certain escrow hold-back.
Tekmira Pharmaceuticals Corporation (“Tekmira”) completed a merger of equals with OnCore Biopharma, Inc. (“OnCore”) whereby OnCore merged with a wholly-owned subsidiary of Tekmira. As a result of the merger, stockholders of OnCore hold approximately fifty per cent (50%) of the total number of outstanding shares of capital stock of Tekmira. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, was approximately USD$750 million and at time of closing USD$964 million.
On August 15, 2003, QLT Inc., a global bio-pharmaceutical and photodynamic therapy company, completed the issuance of US$172.5 million aggregate principal amount of 3 per cent convertible senior notes due in 2023. The notes are convertible into QLT common shares under certain circumstances at an initial conversion price of approximately US$17.80 per share.